Hugh Bowen

The AI Biology company.

Ephos is building the essential infrastructure for the future of computing. We design and manufacture glass-based integrated photonic circuits that power the most advanced classical and quantum devices.

QV Bioelectronics is a VC-backed medical device startup developing an implantable electric field therapy treatment for aggressive brain tumours.

FoodMarble is the world’s first personal digestive tracker. It helps people who experience digestive discomfort track how they respond to different foods. FoodMarble is a hand-held, affordable breath analysis device and associated app that is based on techniques used in gastroenterology departments around the world. The FoodMarble AIRE 2 helps people optimize their diet for their unique digestive system. The FoodMarble AIRE 2 is available to purchase online at foodmarble.com

CroíValve is an early-stage medical device company developing a unique transcatheter device to repair the tricuspid valve.

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who dont respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who dont respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for YAG laser capsulotomy after surgery, our device has the potential to revolutionise cataract surgery in both the human and veterinary markets.

Partner with us and leverage our technology for the development of the next wave of superior protein conjugates and Antibody-Drug-Conjugates! Looking to fast track your development of next generation bioconjugates, staying ahead of your competitors? With the complete freedom to choose where on the protein, we conjugate and optimize for: • Stability, • Aggregation, • Superior efficacy, • Therapeutic window ... and more! The process is simple! 1. Get in touch with us (message us here or visit our website). 2. After you let us know about your protein of interest, we produce different site-specific conjugate versions for you. 3. They are shipped either to you or your CRO. 4. You collect the data you need. 5. Go or no-go decision.

We are a team based in London, that develops a platform to help assess people with Parkinson’s disease better. Motor assessment in Parkinson’s disease is plagued by issues of subjectivity and reproducibility – not to mention systematic biases such as rater drift. To counter this, we are developing a platform, called Kelvin, that can be used from any device (e.g. smartphones or tablets). Named after the famous physicist so beloved of precise measurement, the platform allows researchers to record, score, store and analyse video of Parkinson’s patients during motor assessment. Once captured and organised, the platform uses a cutting-edge computer vision technique, called pose estimation, to objectively track the movement of the patients down to the fingertip level and deliver objective metrics of core symptoms, such as tremor and bradykinesia.

SOSV is the most active deep tech venture capital firm globally, investing at pre-seed (or at startup inception) supporting visionary founders intent on making a profound impact on human and planetary health. SOSV has three deeply resourced locations for founders in San Francisco (SOSV SF), New York (SOSV NY), and Newark (SOSV HAX). Each year, SOSV makes roughly 60 pre-seed investments of up to $550K each, as well as another 150 follow-on investments in deep tech companies. The pre-seed founders spend 4–6 months working side-by-side with SOSV General Partners and the broader team of experts in science and engineering, design and product development, supply chain and product-market fit. Additionally, founders gain access to each location’s office space and equipped lab space.

IndieBio, an @SOSV startup development program, helps the best scientists become entrepreneurs who build breakthrough companies. http://IndieBio.co

Metabolomic Diagnostics is a deep-tech company specialised in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory. Metabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy, her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.

The AI Biology company.

Ephos is building the essential infrastructure for the future of computing. We design and manufacture glass-based integrated photonic circuits that power the most advanced classical and quantum devices.

QV Bioelectronics is a VC-backed medical device startup developing an implantable electric field therapy treatment for aggressive brain tumours.